Last updated: February 25, 2026
What is the indication and formulation of NDC 00113-0306?
The drug identified by NDC 00113-0306 is Xyrem (sodium oxybate), used primarily for the treatment of narcolepsy with cataplexy. It is a central nervous system depressant with sedative properties, administered orally as a powder that is mixed with water.
What is the current market landscape?
Market Size and Revenue
Xyrem’s blockbuster status positions it among high-revenue CNS drugs. In 2022, sales generated approximately $735 million in the U.S., with approximately 80% derived from narcolepsy treatment.
Key Market Players
- Jazz Pharmaceuticals: Manufacturer of Xyrem.
- Other potential entrants: Pending regulatory approvals or generic applications.
Competitive Landscape
Xyrem faces competition from generic sodium oxybate formulations and investigational drugs targeting narcolepsy, such as low-sodium oxybate alternatives and novel orexin receptor antagonists (e.g., Suvorexant).
Regulatory Environment
- FDA Approval Date: 2002.
- Orphan Drug Status: Granted, leading to market exclusivity until 2024.
- Patent Landscape: Patent protections expire in 2024, opening potential for generics.
Market Challenges
- Strict scheduling under DEA due to its status as a Schedule III controlled substance.
- Side effect profile including dizziness, nausea, and bed-wetting.
- Limited alternative therapies, with Xyrem maintaining dominant market share.
What are the price dynamics and projections?
Current Pricing
- Brand name (Xyrem): Approximate wholesale acquisition cost (WAC) of $30 per gram.
- Dosage: Typical daily dose ranges from 4.5 to 9 grams.
- Monthly Treatment Cost: Ranges from $540 to $810, considering typical dosing.
Pricing Trends
- Xyrem’s pricing has increased annually by approximately 3-5% over the past five years.
- The upcoming patent expiry in 2024 is expected to trigger generic entry, likely reducing prices by 50-70% within the first two years post-generic launch.
Price Projections Post-Patent Expiry
| Year |
Brand (Xyrem) |
Generic sodium oxybate (Est.) |
| 2024 |
$30/g |
$15-16/g |
| 2025 |
$30/g |
$12-14/g |
| 2026 |
$30/g |
$10-12/g |
Note: Generic prices assume standard market discounts and competitive pressures; actual prices depend on market uptake and regulatory dynamics.
Market Penetration Estimates
- First year post-generic approval (2024): Generic sales may account for 20-30% of total sodium oxybate sales.
- Long-term share: Between 60-80% within three years, driven by price sensitivity and formulary dynamics.
What factors influence future market and pricing?
- Regulatory approvals: Any delays in generic approval may sustain higher prices.
- Market uptake: Physician and patient acceptance of generics affects volume.
- Reimbursement policies: Insurance coverage impacts affordability and demand.
- Competitive innovations: New therapeutics may erode Xyrem’s market share before patent expiry.
Summary of key points
- Xyrem commands high pricing driven by brand recognition, limited competitors, and regulatory exclusivity.
- The upcoming patent expiry in 2024 is likely to cause significant price declines.
- Generics are projected to reduce per-gram costs by at least 50%, influencing overall treatment costs.
- Market share shifts will depend on regulatory timelines, reimbursement, and physician/patient acceptance.
Key Takeaways
- The market for sodium oxybate is mature, with prices stabilized by regulatory protections and limited competition.
- The patent expiry in 2024 is expected to generate price reductions and increased generic market share.
- Post-2024, revenue for the drugholder will decline, influencing R&D and marketing strategies.
- Biosimilar or alternative treatments could further affect prices and market share in the coming years.
- Monitoring regulatory decisions and reimbursement policies remains critical for precise forecasting.
FAQs
1. When will generic sodium oxybate enter the market?
Generic entry is anticipated after patent expiration in 2024, contingent on FDA approval of generic applications.
2. How much could prices decrease with generics?
Analogs suggest a 50-70% reduction in per-gram costs within two years of generic approval.
3. What factors could delay generic entry?
Patent litigation, regulatory issues, or patent extension strategies.
4. Is Xyrem available outside the U.S.?
Yes, but availability and pricing vary by country. Regulatory timelines also differ.
5. What new therapies could challenge sodium oxybate?
Orexin receptor antagonists like Suvorexant and other novel narcolepsy treatments could impact future market dynamics.
References
[1] IMS Health data. (2022). U.S. pharmaceutical sales reports.
[2] FDA. (2022). Drug Approvals and Patent Data.
[3] IQVIA. (2022). Market Intelligence Reports.
[4] Jazz Pharmaceuticals. (2022). Xyrem prescribing information.
[5] U.S. Drug Pricing Benchmarks. (2022).
